Nature Medicine Original research articles published in Nature Medicine range from basic findings that have clear implications for disease pathogenesis and therapy to the earliest phases of human investigation. Aiming to keep Ph.D. and M.D. readers informed of a wide range of biomedical research findings, the journal publishes the latest advances in cancer biology, vascular biology, neuroscience, inflammatory disease, infectious disease and metabolic disorders, among other fields. Reviews, Perspectives and other commissioned content clarify and give context to these biomedical research advances, and the News section reports on the latest developments in drug research and development. http://feeds.nature.com/nm/rss/current Nature Publishing Group en © 2025 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. Nature Medicine © 2025 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. [email protected]
  • Nature Medicine https://www.nature.com/uploads/product/nm/rss.gif http://feeds.nature.com/nm/rss/current <![CDATA[<b>Alarming rates of malnutrition among preschoolers in Gaza</b>]]> https://www.nature.com/articles/d41591-025-00064-2 <![CDATA[
    See More

    Nature Medicine, Published online: 24 October 2025; doi:10.1038/d41591-025-00064-2

    The first month-by-month analysis of malnutrition in children of preschool age in Gaza reveals the acute impact of aid restrictions and conflict — with the most recent estimates showing more than 50,000 children severely malnourished.]]> <![CDATA[<b>Alarming rates of malnutrition among preschoolers in Gaza</b>]]> Karen O’Leary doi:10.1038/d41591-025-00064-2 Nature Medicine, Published online: 2025-10-24; | doi:10.1038/d41591-025-00064-2 2025-10-24 Nature Medicine 10.1038/d41591-025-00064-2 https://www.nature.com/articles/d41591-025-00064-2 <![CDATA[How HIV research drives health innovation in multiple diseases]]> https://www.nature.com/articles/s41591-025-04019-5 <![CDATA[

    Nature Medicine, Published online: 24 October 2025; doi:10.1038/s41591-025-04019-5

    The future of HIV research — and of the USA’s scientific leadership — depends on bold, sustained action in defense of discovery, investment, and innovation.]]>     <![CDATA[How HIV research drives health innovation in multiple diseases]]> Lawrence CoreyJirair RatevosianChris BeyrerJudith CurrierJoseph EronMyron S. CohenSteven G. Deeks doi:10.1038/s41591-025-04019-5 Nature Medicine, Published online: 2025-10-24; | doi:10.1038/s41591-025-04019-5 2025-10-24 Nature Medicine 10.1038/s41591-025-04019-5 https://www.nature.com/articles/s41591-025-04019-5     <![CDATA[Teaching machines to doubt]]> https://www.nature.com/articles/s41591-025-04013-x <![CDATA[

    Nature Medicine, Published online: 21 October 2025; doi:10.1038/s41591-025-04013-x

    We must build safeguards against AI’s most dangerous feature: its ability to stop us thinking critically.]]>     <![CDATA[Teaching machines to doubt]]> Leo Anthony Celi doi:10.1038/s41591-025-04013-x Nature Medicine, Published online: 2025-10-21; | doi:10.1038/s41591-025-04013-x 2025-10-21 Nature Medicine 10.1038/s41591-025-04013-x https://www.nature.com/articles/s41591-025-04013-x     <![CDATA[Cardiac gene therapy makes a comeback]]> https://www.nature.com/articles/s41591-025-04002-0 <![CDATA[

    Nature Medicine, Published online: 21 October 2025; doi:10.1038/s41591-025-04002-0

    The first-in-human trial of AAV2i8-I1c (AB-1002) — an adenovirus vector that targets a protein phosphatase inhibitor to cardiac muscle — suggests a cautious return of cardiac gene therapy after earlier setbacks, with a new target, dose optimization and improved vector design shaping future directions.]]>     <![CDATA[Cardiac gene therapy makes a comeback]]> Oliver J. MüllerSusanne HilleAnca Kliesow Remes doi:10.1038/s41591-025-04002-0 Nature Medicine, Published online: 2025-10-21; | doi:10.1038/s41591-025-04002-0 2025-10-21 Nature Medicine 10.1038/s41591-025-04002-0 https://www.nature.com/articles/s41591-025-04002-0     <![CDATA[Cardiotropic AAV gene therapy for heart failure: a phase 1 trial]]> https://www.nature.com/articles/s41591-025-04011-z <![CDATA[

    Nature Medicine, Published online: 21 October 2025; doi:10.1038/s41591-025-04011-z

    In a phase 1 dose-escalation study including 11 patients with heart failure who were followed for 12 months, delivery of a cardiotropic adeno-associated viral vector designed to deliver constitutively active protein phosphatase 1 inhibitor 1 to the heart was well tolerated and showed preliminary evidence of efficacy.]]>     <![CDATA[Cardiotropic AAV gene therapy for heart failure: a phase 1 trial]]> Timothy D. HenryEugene S. ChungMonica AlvisiFerzin SethnaDavid R. MurrayJay H. TraverseLothar RoessigLuke RobertsSwarna ReddyYoujun ChenTugba Guven OzkanStacy WebbMonika MittalLeigh ErvinHesham SadekSheila MikhailKobra HaghighiCanwen JiangR. Jude SamulskiEvangelia G. KraniasAnna P. TretiakovaRoger J. Hajjar doi:10.1038/s41591-025-04011-z Nature Medicine, Published online: 2025-10-21; | doi:10.1038/s41591-025-04011-z 2025-10-21 Nature Medicine 10.1038/s41591-025-04011-z https://www.nature.com/articles/s41591-025-04011-z     <![CDATA[Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial]]> https://www.nature.com/articles/s41591-025-03969-0 <![CDATA[

    Nature Medicine, Published online: 21 October 2025; doi:10.1038/s41591-025-03969-0

    In a phase 1 trial, intramuscular injection of synthetic plasmid DNA encoding monoclonal antibodies against SARS-CoV-2 was safe and well tolerated and did not elicit antidrug antibodies.]]>     <![CDATA[Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial]]> Pablo TebasAmi PatelJoseph T. AgnesElizabeth M. ParzychAmanda BaerMaria CaturlaSukanya GhoshMansi PurwarNicole BedanovaChungdhak TsangKnashawn MoralesDinah AmantePaul D. FisherJoseph R. FrancicaLaurent HumeauDaniel W. KulpJesper PallesenPaul LeonMark EsserTrevor R. F. SmithDavid B. Weiner doi:10.1038/s41591-025-03969-0 Nature Medicine, Published online: 2025-10-21; | doi:10.1038/s41591-025-03969-0 2025-10-21 Nature Medicine 10.1038/s41591-025-03969-0 https://www.nature.com/articles/s41591-025-03969-0     <![CDATA[<b>Creativity keeps the brain young</b>]]> https://www.nature.com/articles/d41591-025-00063-3 <![CDATA[

    Nature Medicine, Published online: 20 October 2025; doi:10.1038/d41591-025-00063-3

    A study shows that creativity enhances brain health by improving connectivity in age-vulnerable regions, highlighting the importance of supporting creative activities in public health strategies.]]>     <![CDATA[<b>Creativity keeps the brain young</b>]]> Karen O’Leary doi:10.1038/d41591-025-00063-3 Nature Medicine, Published online: 2025-10-20; | doi:10.1038/d41591-025-00063-3 2025-10-20 Nature Medicine 10.1038/d41591-025-00063-3 https://www.nature.com/articles/d41591-025-00063-3     <![CDATA[<b>A simple strategy to cut malaria infection rates in babies</b>]]> https://www.nature.com/articles/d41591-025-00061-5 <![CDATA[

    Nature Medicine, Published online: 20 October 2025; doi:10.1038/d41591-025-00061-5

    Baby wraps treated with the insecticide permethrin reduced the incidence of malaria in infants by 66%, according to a randomized controlled trial in Uganda.]]>     <![CDATA[<b>A simple strategy to cut malaria infection rates in babies</b>]]> Karen O’Leary doi:10.1038/d41591-025-00061-5 Nature Medicine, Published online: 2025-10-20; | doi:10.1038/d41591-025-00061-5 2025-10-20 Nature Medicine 10.1038/d41591-025-00061-5 https://www.nature.com/articles/d41591-025-00061-5